Get started
Author

Matteo Salsa

Observed institution: Nerviano Medical Sciences
ORCID: 0009-0007-7120-5221
Observed ORCID: 0009-0007-7120-5221
OpenAlex ID: A5092897293
Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al. · Molecular Cancer Therapeutics · 6
Abstract 5805: A novel platform of diversified payloads to drive ADC innovation
2024 · Paolo Orsini, Matteo Salsa, et al. · Cancer Research · 1
Table S5 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S6 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Data from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Figure S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Figure S3 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S3 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S1 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S4 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Data from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S6 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Figure S2 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Figure S1 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Figure S1 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S4 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Table S3 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2023 · Barbara Valsasina, Paolo Orsini, et al.
Works count: 19
Citation count: 7
H-index: 1
I10-index:
Year
Topic
Type